Dosage ; The dose is increased gradually at the start of treatment and
adjusted to the need of individual patient.
The dosage is halved in-patients with severe kidney failure.
Adult: Monotherapy: Initial dose- 300mg daily.
Average dose: 600-1200mg daily.
In severe epilepsy and refractory cases - initial dose 300mg daily.
Studies on children not sufficient
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Trileptal | Novartis Consumers | Harley's Limited | 300mg | 50 | Tablet | per tablet | KES 2,631.00 |
|
Oxcarbazepine More info |
|
|---|---|
| Drug Indication | Primary generalized tonic-clonic seizures and partial seizures with or without secondary generalization, where there are compelling reasons for not giving phenytoin; carbamazepine or valproates as first line therapy. |
| Precautions | Monitor plasma sodium levels before and during therapy; discontinue treatment when signs of renal, hepatic, hematological disorders appear. |
| Contra-Indications | Known hypersensitivity to oxcarbazepine. Atrio-ventricular block. (It should be given under medical supervision only). |
| Side Effects | Tiredness; dizziness; drowsiness and headache; ataxia; tremor; memory and concentration disturbance; paraesthesia; GIT disturbances; rashes; weight gain; decreased libido; irregular menstruation; oedema; hyponatremia and other rare effects. |
| Dosage | The dose is increased gradually at the start of treatment and adjusted to the need of individual patient. The dosage is halved in-patients with severe kidney failure. Adult: Monotherapy: Initial dose- 300mg daily. Average dose: 600-1200mg daily. In severe epilepsy and refractory cases - initial dose 300mg daily. Studies on children not sufficient. |
| Special Information | It is closely related to carbamazepine and is useful in the same seizure types, but it may have an improved toxicity profile. |
| Pregnancy Category | Category D |
| Pregnancy Category Description | Drugs, which have caused, are suspected to have caused, or may be expected to cause an increased rise in the frequency of malformations or irreversible damage. These drugs may also have adverse pharmacological effects required required |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Anticonvulsants |